Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Non Operating Income (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Non Operating Income readings, the most recent being -$12.3 million for Q4 2024.

  • On a quarterly basis, Non Operating Income fell 725.86% to -$12.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$4.6 million, a 52.79% increase, with the full-year FY2025 number at $3.0 million, up 164.22% from a year prior.
  • Non Operating Income hit -$12.3 million in Q4 2024 for Unicycive Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $17.3 million in Q2 2024 to a low of -$12.3 million in Q4 2024.
  • Median Non Operating Income over the past 3 years was -$3000.0 (2022), compared with a mean of -$1.4 million.
  • The widest YoY moves for Non Operating Income: up 53600.0% in 2023, down 49400.0% in 2023.
  • Unicycive Therapeutics' Non Operating Income stood at -$3000.0 in 2022, then tumbled by 49400.0% to -$1.5 million in 2023, then tumbled by 725.86% to -$12.3 million in 2024.
  • The last three reported values for Non Operating Income were -$12.3 million (Q4 2024), $2.2 million (Q3 2024), and $17.3 million (Q2 2024) per Business Quant data.